[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chelsea and Westminster NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":212},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,75,105,127,150,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100602506","electroacupuncture-as-a-treatment-for-refractory-overactive-bladder-100602506",false,"NCT07124390","Electroacupuncture as a Treatment for Refractory Overactive Bladder","Electroacupuncture as a Treatment for Refractory Overactive Bladder: A Feasibility \u002FPilot Randomized Controlled Trial","EAOAB","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Female adults aged 18 years or older.\n* Diagnosed with overactive bladder syndrome (ICIQ-OAB score ≥10).\n* Symptoms present for at least three months and refractory to first-line treatments.\n* Willing to refrain from starting new bladder-related treatments during the study period.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  * Pregnant or planning pregnancy during the study period.\n  * Bleeding disorders.\n  * Severe needle phobia.\n  * Presence of a pacemaker.\n  * Active cancer diagnosis.\n  * Active urinary tract infections or other urological conditions requiring urgent intervention.\n  * Participation in another clinical trial for bladder dysfunction within the past six months.\n  * Neurological conditions affecting continence (e.g., diabetic neuropathy, multiple sclerosis, Parkinson's disease).\n  * Life-threatening infections.\n  * Severe cognitive deficits, unconsciousness, dementia (e.g., Alzheimer's or other neurodegenerative diseases).\n  * History of incontinence surgery.\n  * Previous acupuncture for OAB within the past two months.\n  * History of thromboses.\n  * Recovering from or suffering from a serious illness or major surgery.","FEMALE","18 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a single-site feasibility randomised controlled trial evaluating the feasibility and acceptability of electroacupuncture (EA), percutaneous tibial nerve stimulation (PTNS), and sham electroacupuncture in women with refractory overactive bladder (OAB) who have not achieved satisfactory improvement following standard pelvic health physiotherapy.\n\nThe primary aim is to determine whether a larger definitive trial is feasible by assessing recruitment, consent, retention, treatment adherence, data completeness, intervention delivery, blinding credibility, safety, and participant acceptability.\n\nThirty-six participants will be randomly allocated to receive electroacupuncture, PTNS, or sham electroacupuncture over a 12-week treatment period. Outcome assessments will be completed at baseline, 6 weeks, 12 weeks, 6 months, and 12 months.\n\nThe findings will inform the design of a future definitive randomised controlled trial and contribute to the evidence base for non-pharmacological treatment options for overactive bladder.",[27,28,29],"Over Active Bladder","Urinary Incontinence (UI)","Nocturia",[31,32,33,34],"Electric-Acupuncture","Acupuncture","PTNS","Neuromodulation","NOT_YET_RECRUITING","2026-06-13",{"date":38,"type":39},"2026-06-16","ACTUAL",{"date":41,"type":21},"2026-07-01",{"date":43,"type":21},"2027-07-30",{"name":45,"class":46},"Chelsea and Westminster NHS Foundation Trust","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100575706","endometrioma-sclerotherapy-and-ovarian-preservation-100575706","NCT06775769","Endometrioma Sclerotherapy and Ovarian Preservation","Endometrioma Sclerotherapy and Ovarian Preservation: a Randomised Control Trial of Laparoscopic Sclerotherapy vs Traditional Excision of Endometrioma","ENDOSAVE","Inclusion Criteria:\n\n* Female (XX genotype, assigned female at birth)\n* Age 18-40\n* Finding of suspected uni- or bi-lateral ovarian endometrioma(ta) of ≥ 2cm on TVUSS and\u002For pelvic MRI scan (TVUSS, a uni- or multi-locular ovarian cystic lesion with low level echoes and diffuse homogeneous ground glass appearance; MRI any of, ovarian lesion hyperintense T1 without loss of signal on T1 fat-suppressed images, hypointense T2 exhibiting shading sign and\u002For T2 dark spot sign, variable restricted diffusion on DWI)\n* Appropriate to be listed for laparoscopic excision of endometrioma (Endometrioma ≥2cm, pain symptoms attributable to endometriosis where medical management is unsuccessful or unacceptable to the patient, to facilitate ART)\n\nExclusion Criteria:\n\n* Postmenopausal status\n* Suspicion of malignancy\n* Unable to undergo TVUSS\n* Declines to take part in the study\n* Unable to understand verbal or written information in English\n* Lack of capacity to consent at the point of recruitment\n* Known safeguarding issues","45 Years",{"count":58,"type":21},60,[24],"A randomised controlled trial assessing ovarian reserve after laparoscopic ethanol sclerotherapy of ovarian endometrioma compared to standard treatment of surgical excision of endometrioma.\n\nSecondary outcomes will include endometrioma recurrence, symptomatology and inflammatory environment.",[62],"Endometrioma",[62,64,65],"Endometriosis","Sclerotherapy","RECRUITING","2025-11-24",{"date":69,"type":39},"2025-11-25",{"date":71,"type":39},"2025-02-21",{"date":73,"type":21},"2027-12-31",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100608489","spoken-animation-for-labour-epidural-100608489","NCT07202221","Spoken Animation for Labour Epidural","Evaluation of Spoken Animation as a Tool for Imparting Information About Epidural Labour Analgesia","SALE","Inclusion Criteria:\n\n• Primiparous birthing people presenting for induction of labour.\n\nExclusion Criteria:\n\n* Patient refusal\n* Unable to speak English or any of the seven language translations provided\n* Epidural contraindicated\n* Previous Epidural for any reason\n* Any significant health concerns",true,{"count":85,"type":21},120,[24],"The purpose of this study is to evaluate a new animated information film as a tool for introducing the concept of epidural as a method of labour pain relief to expectant women.\n\nThe main question that the study is designed to answer is:\n\nCompared to written information alone, does the addition on a short animated introductory film reduce decisional conflict for expectant women regarding the use of epidural pain relief.\n\nSecondary outcomes tested will be change in anxiety and satisfaction scores after receiving the information.\n\nStudy participants will include women expecting their first baby, presenting to hospital for induction of labour. They will be asked to fill out a questionnaire regarding thoughts and feelings around epidural, before and after receiving information about the procedure. Participants will be randomised to receive either traditional written information alone or with the addition of the animated film.\n\nA smaller number of participants will also be asked to participate in a short interview about the animated film.",[89],"Labour Pain",[91,92,93,94,95,96],"labour","consent","information","animation","obstetric","epidural","2025-09-23",{"date":99,"type":39},"2025-10-01",{"date":101,"type":21},"2025-10-15",{"date":103,"type":21},"2026-10-15",{"name":45,"class":46},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":47},"100452899","phase-2-mifepristone-outpatient-labour-induction-100452899","NCT05177510","Mifepristone Outpatient Labour Induction","MOLI","Inclusion Criteria:\n\n1. Pregnant women between 36+5 and 41+5 weeks of gestation\n2. Singleton pregnancy\n3. Aged 18 years or older\n4. Unfavourable cervix (Bishop Score less than or equal to 6)\n5. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements.\n\nExclusion Criteria:\n\n1. Breech presentation\n2. Early labour\n3. Contraindication to vaginal birth (placenta praevia, transverse lie, known or suspected cephalo-pelvic disproportion or other factor contraindicated to vaginal birth in the opinion of the investigator)\n4. Fetal growth restriction with oligohydramnios and\u002For abnormal Dopplers\n5. Presence of reduced fetal movements requiring urgent delivery, abnormal CTG or recent antepartum haemorrhage requiring immediate delivery\n6. Medical conditions:\n\n   i. sexually transmitted infections (active infections only) ii. bleeding disorders, on anticoagulants, steroid or aspirin therapy iii. prior uterine operations (Caesarean Section or myomectomy)\n7. Contra-indications to mifepristone including chronic adrenal, hepatic, renal failure\n8. Hypersensitivity to mifepristone or to any excipients, or malnutrition\n9. Severe asthma uncontrolled by therapy and inherited porphyria\n10. Any investigational drug with an expected interaction with mifepristone which has been administered within 30 days prior to the trial drug administration.",{"count":113,"type":21},400,[115],"PHASE2","The number of women having an induction of labour is increasing and is currently used in 33% of pregnancies for a range of medical reasons. The majority of women are admitted to hospital to have their labour induced, using methods which are protracted and associated with a poor birth experience, making them both costly and unpopular. Further, current methods of outpatient induction are unsuitable, unsafe and\u002For have a poor acceptability. The COVID-19 pandemic has driven a reduction in the number of face-to-face interactions taking place across all areas of medicine. Proving the efficacy and safety of Mifepristone would significantly reduce pre-labour admission rates and hospital length of stay for pregnant women, who are at particularly higher risk of COVID-19, and reduce delivery costs.",[118],"Labor, Induced","2025-09-03",{"date":121,"type":39},"2025-09-10",{"date":123,"type":39},"2023-08-25",{"date":125,"type":21},"2026-12-31",{"name":45,"class":46},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":83,"sex":17,"minAge":134,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100589636","lower-urinary-tract-symptoms-in-transmasculine-patients-undergoing-metoidioplasty-and-their-acceptability-of-pelvic-floor-muscle-training-assessed-by-a-pelvic-obstetric-and-gynaecological-physiotherapist-100589636","NCT06956989","Lower Urinary Tract Symptoms in Transmasculine Patients Undergoing Metoidioplasty and Their Acceptability of Pelvic Floor Muscle Training Assessed by a Pelvic, Obstetric and Gynaecological Physiotherapist","LUTS-POGP","Inclusion Criteria:\n\nHave capacity to consent.\n\nDiagnosis of gender dysphoria and have lived in a gender role that is congruent to their gender identity for minimum of 12 months.\n\nTransmasculine patients referred to CCGS for masculinising lower genital reconstructive surgery having received two signatures confirming suitability for reconstructive surgery.\n\nUndergoing metoidioplasty\u002Fphalloplasty.\n\nAge \\>17 years old.\n\nOn systemic testosterone therapy for more than 12 months.\n\nExclusion Criteria:\n\n* Age less than 18 years.\n\nNot undergoing metoidioplasty\u002Fphalloplasty.","17 Years",{"count":136,"type":21},50,"OBSERVATIONAL","Lower urinary tract symptoms in transmasculine patients undergoing metoidioplasty and their acceptability of pelvic floor muscle training assessed by a Pelvic, Obstetric and Gynaecological Physiotherapist.\n\nStudy Design\n\nProspective observational pilot study\n\nStudy Participants\n\nTransmasculine patients undergoing metoidioplasty\n\nPlanned Sample Size\n\n50\n\nPlanned Study Period\n\n2025\u002F26\n\nObjectives\n\nUnderstand the acceptability of first-line pelvic floor muscle training (PFMT) treatment in transmasculine patients undergoing metoidioplasty\n\nBackground incidence of lower urinary tract symptoms (LUTS) in transmasculine patients undergoing surgery\n\nEndpoints\n\nAcceptability of PFMT questionnaire\n\nInternational Prostate Symptom Score (I-PSS) and International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) questionnaires and uroflowmetry",[140,141],"Lower Urinary Tract Symptoms","Transgenderism","2025-04-25",{"date":144,"type":39},"2025-05-04",{"date":146,"type":21},"2025-08",{"date":148,"type":21},"2027-08",{"name":45,"class":46},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":158,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100431020","phase-3-efficacy-of-doravirine--dolutegravir-dual-therapy-in-the-context-of-antiretroviral-therapy-switch-100431020","NCT04892654","Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch","Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)","DORDOL","Inclusion Criteria:\n\n* HIV-1 infected, 18 years or older\n* On stable \\& suppressive triple cART for at least 6 months\n* No evidence of resistance to DOR or DTG\n* No laboratory abnormalities, medical\u002Fpsychiatric conditions or alcohol\u002Fdrug use considered a barrier to participation by investigators\n* Women who are pre-menopausal and sexually active should be on one of the following methods of contraception:\n\n  * Implant\n  * Depot injection\n  * Intra-uterine device or system\n  * Oral hormonal contraception\n\nExclusion Criteria:\n\n* History of virological failure on an NNRTI in absence of a post-failure genotypic resistance test proving absence of resistance to DOR\n* History of virological failure on an INSTI in absence of a post-failure genotypic resistance test proving absence of resistance to DTG (INSTI mutations that will lead to the need of administering DTG twice-daily are considered as resistance to DTG - and the subject will be considered NOT eligible)\n* Concomitant medication contra-indicated with DTG or DOR\n* Haemoglobin \\\u003C9 g\u002FdL\n* Platelets \\\u003C80,000\u002Fmm3\n* Creatinine clearance \\\u003C30 mL\u002Fmin\n* AST or ALT ≥5N\n* Acute Hepatitis A infection.\n* Concomitant DAA for anti-HCV therapy\n* Known acute or chronic viral hepatitis B or C.\n\n  * Individuals testing positive for HBcAb, but negative HBsAg\u002FHBeAg, may be included on the trial.\n  * Individuals with positive anti-HCV results, but with HCV RNA not detected may be included on the trial.\n* Pregnant or breastfeeding women","ALL",{"count":160,"type":21},150,[162],"PHASE3","Combination antiretroviral therapy (cART) HIV treatments are associated with increased quality of life, and a normalisation of life expectancy in people living with HIV. However, long-term use of cART can lead to side-effects through exposure to drug-related toxicity.\n\nFor this reason researchers are interested in looking at alternative therapies that might expose patients to fewer and less severe side effects while providing the same quality of care as antiretroviral therapies most often used to treat HIV.\n\nThe purpose of this study is to investigate if the study drug combination that is being tested (doravirine + dolutegravir) is safe compared with other triple cART regimens.",[165],"HIV-1-infection",[167,168,169,170],"HIV","Doravirine","Dolutegravir","cART","2023-10-24",{"date":173,"type":39},"2023-10-25",{"date":175,"type":39},"2022-08-17",{"date":177,"type":21},"2027-11-30",{"name":45,"class":46},3,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":190,"conditions":191,"keywords":197,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":47},"100497121","effect-of-obesity-diabetes-and-bariatric-surgery-on-pregnancy-outcomes-100497121","NCT05753124","Effect of Obesity, Diabetes and Bariatric Surgery on Pregnancy Outcomes","Investigation and Study of Pregnancy in Overweight or Diabetic Women and the Effect of Bariatric Surgery on Pregnancy Outcomes","Inclusion Criteria:\n\n* Pregnant women with normal size (BMI \\\u003C30)\n* Pregnant women with obesity (BMI ≥30)\n* Pregnant women with glucose disorders\n* Pregnant women with previous bariatric surgery\n\nExclusion Criteria:\n\n* Pregnant women less than 18 years of age\n* Pregnant women with twins\u002Ftriplets","50 Years",{"count":189,"type":21},700,"The obesity epidemic is growing worldwide and in the UK this is perpetuated with a third of women classified as overweight\u002Fobese in 2020. Many of these woman are of childbearing age and go on to have high risk pregnancies which are often complicated by gestational or pre-existing (type 2 diabetes mellitus (GDM, T2DM). Bariatric surgery is the most successful treatment of sustainable weight loss and is associated with a reduction in rates of GDM, pre-eclampsia, delivery of large babies but increased risk of delivery of small babies and preterm delivery.\n\nThe aims of the study are to investigate the maternal and fetal\u002Fneonatal, biophysical and biochemical, intra-uterine environment and postnatal profile of pregnancies:\n\n1. affected by maternal obesity and\u002For GDM\u002FT2DM compared to pregnancies with normal maternal body mass index (BMI).\n2. with previous maternal bariatric surgery compared to pregnancies without previous bariatric surgery but matched for maternal pre-surgery and early pregnancy BMI.",[192,193,194,195,196],"Obesity","Pregnancy in Diabetic","Pregnancy Complications","Pregnancy Related","Bariatric Surgery Status Complicating Pregnancy",[198,199,200,201,202,203],"Pregnancy","Gastric sleeve","Gastric bypass","Bariatric surgery","Birth weight","Glucose intolerance","2023-03-01",{"date":206,"type":39},"2023-03-03",{"date":208,"type":39},"2015-05",{"date":210,"type":21},"2027-10",{"name":45,"class":46},""]